TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Inclusion Criteria: * Age: 16 years to 90 years * Histologically diagnosed as primary/relapsed/metastasized Cancer * Expected life span more than 3 months * Karnofsky≥60% or ECOG score 0-2 * Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available. * Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated * At least 1 evaluable tumor lesion * Hematology and Chemistry（within 7 days prior to enrollment）: * Absolute count of white blood cells≥2.5×10\^9/L * Absolute count of neutropils≥1.5×10\^9/L * Absolute count of lymphocytes ≥0.7×109/L * Platelet count≥100×10\^9 * hemoglobin≥90 g/L * Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days) * International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days) * Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min * Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN) * Totol bilirubin≤1.5×ULN * No absolute or relative contraindications to operation or biopsy * Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion * Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs * Be able to understand and sign the informed consent document; * Be able to stick to the follow-up visit plan and other requirements in the agreement. Exclusion Criteria: * Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment * Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40% * Significant cardiovascular anomalies according to any of the following definitions: * New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant * Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc. * Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive. * Severe physical or mental diseases; * Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection). * Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy. * History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy. * Having received immunotherapy and developed an irAE level greater than Level 3. * Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded). * Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy. * Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.